Polycystic ovary syndrome (PCOS) is a prevalent hormonal disorder affecting women during their reproductive years, recognized as a leading cause of irregular menstrual cycles and infertility. Recently, a consensus in The Lancet has led to the renaming of PCOS to Polyendocrine Metabolic Ovarian Syndrome (PMOS) to better represent its complex, systemic nature. While both PCOD (Polycystic Ovarian Disease) and PCOS relate to hormonal imbalances, they differ significantly in severity and impact. PCOD is a milder condition confined mainly to the ovaries, characterized by the production of immature eggs and multiple cysts, often manageable through lifestyle modifications. In contrast, PCOS involves more severe hormonal disruptions, leading to insulin resistance, obesity, and long-term health risks such as diabetes and heart disease. Effective management of PCOS/PMOS requires a comprehensive approach, including medical intervention to address hormonal imbalances and insulin resistance, alongside lifestyle changes. The rebranding aims to correct misconceptions and emphasize the broader implications of the syndrome on women's health.